BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout

BioNTech has linked gotistobart to median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.